Cellmid just cannot take a trick, can it?
Just when it announces two months ago that it is in negotiations with a buyer to divest Lyramid, along comes Covid and spoils everything.
And what have Cellmid/Lyramid been doing about Covid? They have just got OUT of the Covid antibody business. And now they watch Ellumehealth pocket 230 million dollars for going INTO the Covid antigen business.
Blooming Covid.
Life can be a beach.
- Forums
- ASX - By Stock
- AN1
- Ann: Cellmid Publishes Data on Novel Proprietary FGF5 Aptamer
Ann: Cellmid Publishes Data on Novel Proprietary FGF5 Aptamer, page-10
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable